FeesSafety
Pluang+

West Fraser indefinitely curtails two mills amid weak wood product demand, reports Q3 loss and plans $200M-$220M asset impairment.

Company Fundamentals
29 Oct 2026, 00:30 WIB
PRNewsWire
View Source
Bearish
West Fraser indefinitely curtails two mills amid weak wood product demand, reports Q3 loss and plans $200M-$220M asset impairment.

West Fraser Timber announced indefinite curtailment of its Huguley OSB mill in Alabama and lumber mill in Arkansas due to continued weak demand in new home construction and renovations. The company reported a Q3 2026 loss of $80 million and adjusted EBITDA of $38 million on $1.363 billion sales. These curtailments will reduce OSB and lumber capacity significantly and lead to a $200-$220 million asset impairment in Q4. West Fraser also refinanced debt to strengthen liquidity and expects 2026 shipments to be at the lower end of guidance amid ongoing market challenges.

West Fraser Timber's Q3 2026 results and curtailments provide context for basic materials investors. For readers following this sector, here is Pluang's market snapshot as of Oct 29, 2026 03:52 WIB: Of 83 priced US basic materials stocks, 45 rose and 37 fell. Notable movers include VALE at USD 11.47 (-3.12%), IP at USD 34.42 (+3.12%), and IFF at USD 90.54 (-2.86%). Typical hold times on Pluang range from 5 to 111 days, with mixed buy/sell order activity.

More News

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market is projected to grow from $5.8 billion in 2026 to $8.04 billion by 2032, at a CAGR of 5.54%. Growth is fueled by expanding chain cafes, specialty coffee methods like cold brew, and rising homegrown brands. However, rising coffee...

Market News
Neutral
22 minutes ago
FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 ...

Market News
Bullish
22 minutes ago
LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED held a global media test drive event at Chery's International Headquarters in Vu Hồ, featuring the luxury MPV LLounge and the high-performance Stormax SUV. Media representatives and influencers from UAE, Thailand, and Indonesia experienced a 1...

Market News
Bullish
22 minutes ago
Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Kirby McInerney LLP is investigating NVE Corporation for possible violations of federal securities laws after the company reported a 47% revenue decline and a 33.7% stock price drop following its Q2 fiscal 2027 results. The revenue fall was attribute...

Market News
Bearish
2 hours ago
Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...

Market News
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App